Prime Medicine (PRME) Accumulated Expenses (2021 - 2026)
Prime Medicine's (PRME) quarterly Accumulated Expenses came in at $8.1 million in Q1 2026, down 11.89% YoY from $9.2 million in Q1 2025, and down 35.73% on a QoQ basis from $12.6 million in Q4 2025.
Prime Medicine (PRME) Accumulated Expenses (2021 - 2026) Analysis & Trends
Prime Medicine (PRME) has 6 years of Accumulated Expenses data on file, last reported at $8.1 million in Q1 2026.
- Quarterly Accumulated Expenses fell 11.89% year-over-year to $8.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.1 million (down 11.89% YoY) and the FY2025 annual result came in at $12.6 million, down 20.77% from the prior year.
- Accumulated Expenses declined to $8.1 million in Q1 2026, from $12.6 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $18.7 million in Q3 2024 to a low of $300000.0 in Q2 2023.
- A 5-year average of $10.6 million and a median of $10.9 million in 2024 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2022 — Accumulated Expenses tumbled 71.26% — and 2024, when it jumped 3531.67%.
- Tracing PRME's Accumulated Expenses over 5 years: stood at $10.7 million in 2022, then surged by 32.02% to $14.1 million in 2023, then rose by 12.71% to $15.9 million in 2024, then declined by 20.77% to $12.6 million in 2025, then tumbled by 35.73% to $8.1 million in 2026.
- The last three Accumulated Expenses figures came in at $8.1 million (Q1 2026), $12.6 million (Q4 2025), and $11.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Prime Medicine | 558.48 Mn | 558.48 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.98 Mn |
| Mar 31, 2026 | 8.10 Mn |
| Dec 31, 2025 | 12.60 Mn |
| Sep 30, 2025 | 11.00 Mn |
| Jun 30, 2025 | 12.16 Mn |
| Mar 31, 2025 | 9.19 Mn |
| Dec 31, 2024 | 15.90 Mn |
| Sep 30, 2024 | 18.68 Mn |
| Jun 30, 2024 | 10.90 Mn |
| Mar 31, 2024 | 7.61 Mn |
| Dec 31, 2023 | 14.11 Mn |
| Sep 30, 2023 | 14.02 Mn |
| Jun 30, 2023 | 300,000.00 |
| Mar 31, 2023 | 7.54 Mn |
| Dec 31, 2022 | 10.69 Mn |
| Sep 30, 2022 | 6.53 Mn |
| Dec 31, 2021 | 37.19 Mn |